Skip to Main Content
Contribute Try STAT+ Today

The key ingredient in a controversial medicine used to prevent premature births is associated with a higher risk of cancer in people that were exposed to the treatment in utero, according to a new study.

Specifically, those exposed to 17-OHPC had nearly double the risk of any cancer compared to those not exposed, although the risk appeared to vary depending on the cancer. For instance, children exposed to 17-OHPC had more than 34 times greater risk of brain cancer, and as adults had more than five times greater risk of colorectal and prostate cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment